Skip to main content
ATXI logo

ATXI · Avenue Therapeutics, Inc. · Executive Compensation

Track ATXI — free
$0.38 -0.05 (-10.71%) At close · Mar 19
Market Cap
$848,783
Shares
3.29M
Volume · Mar 19 173.84K Avg daily vol (3M) 426.7K

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2022
Executive Total
Lucy Lu $570,859
Alexandra MacLean $280,542
Joseph Vazzano $21,335
David Jin —
Fiscal 2021
Executive Total
Lucy Lu $1,082,128
Joseph Vazzano $441,325
David Jin —
Alexandra MacLean —
Fiscal 2020
Executive Total
Lucy Lu $443,027
Joseph Vazzano $214,890
Fiscal 2019
Executive Total
Lucy Lu $639,783
Joseph Vazzano $258,779
Fiscal 2018
Executive Total
Lucy Lu $1,594,633
Joseph Vazzano $354,528

Executive changes

Person Change Filed
Lindsay A. Rosenwald, M.D. Appointed 2024-06-26
Alexandra MacLean, M.D. Appointed 2024-06-26
Curtis Oltmans Already on the board
Since at least 2021: re-election or new board role
2024-06-26
Faith Charles Already on the board
Since at least 2022: re-election or new board role
2024-06-26
Neil Herskowitz Already on the board
Since at least 2015: re-election or new board role
2024-06-26
Jay Kranzler, M.D., Ph.D. Appointed 2024-06-26
Jay Kranzler, M.D., Ph.D. Appointed 2023-03-08
Alexandra MacLean, M.D. Appointed 2023-03-08
E. Garrett Ingram Resigned 2022-11-04
Jaideep Gogtay Resigned 2022-11-04
Alexandra MacLean, M.D. Appointed 2022-08-03

Leadership

Key facts CIK 1644963 CUSIP 05360L403 Visit website Investor relations